Global Bronchitis Treatment market – Snapshot
Bronchitis is a respiratory disease that causes inflammation in the airways, also known as bronchi, of the lungs. It leads to irritation and inflammation of the lining of bronchial tubes, which are responsible for carrying air to and from the lungs. Shortness of breath, cough with thick mucus, chest discomfort, wheezing, fatigue, slight fever, and chills are common symptoms of bronchitis. Bronchitis can be either acute or chronic. Acute bronchitis, also known as chest cold, is a temporary inflammation of the bronchial tubes that leads to cough and mucus production and lasts for up to three weeks. On the other hand, chronic bronchitis is a type of chronic obstructive pulmonary disease (COPD), a long-term, serious condition, which leads to production of cough with thick mucus and lasts for up to three months. The global bronchitis treatment market was worth US$ 3,432.62 Mn in 2017. It is expected to expand at a CAGR of 3.6% from 2018 to 2026.
Anti-inflammatory drugs, mucolytics, and bronchodilators are widely utilized for the treatment of bronchitis. Increase in morbidity and mortality associated with bronchitis across the globe is a major factor driving the global bronchitis market. However, stringent regulatory scenario and patent expiry of key drugs restrain the global market.
The global bronchitis treatment market can be segmented based on type, drug class, distribution channel, and region. Furthermore, in terms of type, the market can be divided into chronic bronchitis and acute bronchitis. The chronic bronchitis segment is likely to account for a leading share of the global market during the forecast period, owing to high morbidity and mortality rate. Based on drug class, the bronchitis treatment market can be divided into antibiotics, anti-inflammatory drugs, bronchodilators, and mucolytics. In terms of distribution channel, the market can be classified into hospital pharmacies, retail pharmacies, and online pharmacies. The retail pharmacies segment held significant share of the market in 2017, due to a rise in the sale of over-the-counter bronchitis therapeutics.
Based on region, the global bronchitis treatment market has been segmented into five major regions: North America, Europe, Asia Pacific, Latin America, and Middle East & Africa. North America and Europe accounted for a major share of the global market in 2017. High prevalence of bronchitis and presence of a large geriatric population that is more prone to develop bronchitis fuelled the demand for bronchitis therapeutics in these regions. The bronchitis treatment market in Asia Pacific is likely to expand at a high CAGR during the forecast period. Increase in incidence of bronchitis, adoption of western lifestyle, excessive cigarette smoking, and rise in health care expenditure are projected to fuel the market in the region during the forecast period. Latin America and Middle East & Africa are expected to present significant opportunities in the bronchitis market during the forecast period.
Request Brochure of Report: https://www.transparencymarketresearch.com/sample/sample.php?flag=B&rep_id=61416
Key players operating in the global bronchitis treatment market include AstraZeneca, Novartis AG, GlaxoSmithKline plc, Dr. Reddy’s Laboratories Ltd., Melinta Therapeutics, Sanofi Aventis, and Boehringer Ingelheim International GmbH. These companies have established their stand in the market and enjoy brand loyalty among customers. They have a diverse product offering and an extensive distribution system across the world. Moreover, entry of small players, especially in the emerging markets of Asia, is being witnessed. However, stringent regulatory framework and high-quality standards set by market leaders are anticipated to restrain the penetration of new entrants in the market.